Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Levesque

Showing results (181-190 of 281) with videos related to

Pageof 29
Sort By:
Oncotarget|October 30, 2016
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistanceMarieke I G Raaijmakers, Daniel S Widmer, Apurva Narechania, et al.
International Journal of Molecular Sciences|September 14, 2024
Distinct Variations in Gene Expression and Cell Composition across Lichen Planus SubtypesCadri Knoch, Veronika Baghin, Patrick Turko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentStefan Diem, Mirjam Fässler, David Bomze, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2000
CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptorR Doyonnas, J Yi-Hsin Chan, L H Butler, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Science Advances|August 14, 2018
Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spreadQiaoli Ma, Lothar C Dieterich, Kristian Ikenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2020
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint InhibitionLucas Basler, Hubert S Gabryś, Sabrina A Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesMarie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
BMC Medical Informatics and Decision Making|October 31, 2018
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsFranziska Singer, Anja Irmisch, Nora C Toussaint, et al.
Cancer Research|September 7, 2018
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor GrowthChristine Pich, Patrick Meylan, Beatris Mastelic-Gavillet, et al.
Pageof 29

Showing results (181-190 of 281) with videos related to

Sort By:
Pageof 29
Oncotarget|October 30, 2016
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistanceMarieke I G Raaijmakers, Daniel S Widmer, Apurva Narechania, et al.
International Journal of Molecular Sciences|September 14, 2024
Distinct Variations in Gene Expression and Cell Composition across Lichen Planus SubtypesCadri Knoch, Veronika Baghin, Patrick Turko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentStefan Diem, Mirjam Fässler, David Bomze, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2000
CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptorR Doyonnas, J Yi-Hsin Chan, L H Butler, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Science Advances|August 14, 2018
Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spreadQiaoli Ma, Lothar C Dieterich, Kristian Ikenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2020
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint InhibitionLucas Basler, Hubert S Gabryś, Sabrina A Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesMarie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
BMC Medical Informatics and Decision Making|October 31, 2018
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsFranziska Singer, Anja Irmisch, Nora C Toussaint, et al.
Cancer Research|September 7, 2018
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor GrowthChristine Pich, Patrick Meylan, Beatris Mastelic-Gavillet, et al.
Pageof 29